PATENT CLAIM ANALYSIS

Application Number: 16221135
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-05
Patent Classification: ["514", "179000"]

Abstract:
Provided herein are pharmaceutical compositions comprising a therapeutically effective amount of a lipophilic compound and a pharmaceutically acceptable carrier adapted for pen-ocular transdermal delivery of the lipophilic compound to one or more periorbital glands and/or the ocular surface tissues of a subject. Further provided herein are methods of using such pharmaceutical compositions for providing relief of one or more signs or symptoms of an ocular disease, methods of using one or more Meibomian glands (and meibum therein) as a drug delivery system for a lipophilic compound (e.g., a steroid) to the ocular surface, and kits related thereto.

Claim (Index 6):
The pharmaceutical composition of  claim 1 , wherein the pharmaceutically acceptable carrier is selected from the group consisting of an ointment, cream, lotion, gel, emulsion, suspension, oil, foam, transdermal patch, spray, and any combinations thereof.

Metadata:
- Claim Count in Document: 38.0
- Percentile: 98.0
- Lexical Diversity: 1.76667
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['13004764', '15555527', '15051654', '15946709', '15676968']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7473533738790787
- 35 USC 102 Novelty (BERT): 0.495202636379881
- Combined Prediction Score: 0.722138300129159
- Mean Citation Score: 222.6128
- Max Citation Score: 227.9993
- Similarity Product: 175.83793918707372

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test